A Study to Investigate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease (SCD)
Trial details
- Registry ID
- NCT07656415
- Drugs studied
- Mitapivat
TrialRedline tracks 14 clinical trials sponsored by Agios Pharmaceuticals, Inc.: 8 Phase 3, 2 Phase 2 / 3, 4 Phase 2.
Company identity checked against sources
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Study to Investigate AG-236 in Subjects ≥18 Years of Age With Polycythemia VeraNCT07859423 | AG-236 | Not yet recruiting | 2030-08Estimated |
| A Study Evaluating the Efficacy and Safety of Mitapivat (AG-348) in Participants With Sickle Cell Disease (RISE UP)NCT05031780 | Mitapivat | Active not recruiting | 2025-10-30Actual |
| Trial | Drugs studied | Status | Primary completion |
|---|---|---|---|
| A Dose-Finding Study of Tebapivat to Assess Efficacy, and Safety in Participants With Sickle Cell Disease (SCD)NCT06924970 | Tebapivat | Active not recruiting | 2026-05-12Actual |
| A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)NCT05490446 | Tebapivat | Active not recruiting | 2026-03-17Actual |
| A Study to Determine the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of AG-348 in Adult Participants With Non-transfusion-dependent ThalassemiaNCT03692052 | AG-348 | Active not recruiting | 2020-08-20Actual |
| A Study of AG-348 in Adult Participants With Pyruvate Kinase (PK) DeficiencyNCT02476916 | AG-348 | Completed | 2017-05-08Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2027-02-01Day | MitapivatAgios Pharmaceuticals, Inc. · AGIO | Company-disclosed PDUFA goal dateAnnounced review target | sickle cell disease | Open original sourceRead source excerptWe submitted a supplemental New Drug Application, or sNDA, for the U.S. accelerated approval of mitapivat in sickle cell disease, or SCD, in May 2026, which was accepted with priority review by the FDA and granted a Prescription Drug User Fee Act, or PDUFA, goal date of November 1, 2026. The PDUFA goal date was subsequently extended to February 1, 2027 following our response to an FDA information request to inform its evaluation as to whether a REMS is necessary for mitapivat in SCD. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2027-02-01Day | MitapivatAgios Pharmaceuticals, Inc. · AGIO | Company-disclosed PDUFA goal dateAnnounced review target | SCD | Open original sourceRead source excerptWe submitted an sNDA for the U.S. accelerated approval of mitapivat in SCD in May 2026, which was accepted with priority review by the FDA and granted a PDUFA goal date of November 1, 2026. The PDUFA goal date was subsequently extended to February 1, 2027 following our response to an FDA information request to inform its evaluation as to whether a REMS is necessary for mitapivat in SCD. First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
| 2027-02-01Day | MitapivatAgios Pharmaceuticals, Inc. · AGIO | Company-disclosed PDUFA goal dateAnnounced review target | sickle cell disease | Open original sourceRead source excerptNew PDUFA goal date for mitapivat sickle cell disease sNDA set for February 1, 2027; company is launch-ready and in labeling discussions with FDA First seen: 07 Nov 2026 · Evidence last checked: 07 Nov 2026 |
Names as written in the registry records.
NCT06924970 · Agios Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: May 2026. After: 12 May 2026.
NCT07656415 · Agios Pharmaceuticals, Inc.
Before: Not yet recruiting. After: Recruiting.
NCT07517133 · Agios Pharmaceuticals, Inc.
Before: Not yet recruiting. After: Recruiting.
Before: Not yet recruiting. After: Recruiting.
NCT05490446 · Agios Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: Mar 2026. After: 17 Mar 2026.
NCT06924970 · Agios Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: 56 participants (planned). After: 59 participants (actual).
Before: Recruiting. After: Active not recruiting.
NCT05490446 · Agios Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: 82 participants (planned). After: 87 participants (actual).
Before: Nov 2025. After: Mar 2026.
Before: Recruiting. After: Active not recruiting.
NCT05031780 · Agios Pharmaceuticals, Inc.
Before: Estimated. After: Actual.
Before: Dec 2025. After: 30 Oct 2025.